Demyelination as a complication of new immunomodulatory treatments.

Détails

ID Serval
serval:BIB_0E58E112F7EF
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Demyelination as a complication of new immunomodulatory treatments.
Périodique
Current Opinion In Neurology
Auteur(s)
Lysandropoulos A.P., Du Pasquier R.A.
ISSN
1473-6551[electronic], 1080-8248[linking]
Statut éditorial
Publié
Date de publication
2010
Peer-reviewed
Oui
Volume
23
Numéro
3
Pages
226-233
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review Publication Status: ppublish
Résumé
Purpose of review: This review discusses demyelinating events of the nervous system that have been associated with new immunomodulatory treatments, in particular monoclonal antibodies (mAbs).
Recent findings: Natalizumab, a mAb targeting the alpha-4 integrins, which is efficient in relapsing-remitting multiple sclerosis, has been associated with progressive multifocal leukoencephalopathy (PML). We will review the putative mechanisms linking natalizumab with JC virus, the agent of PML. Efalizumab, a mAb targeting a member of the integrin family, CD11a, was approved for the treatment of psoriasis, but had to be withdrawn in 2009 because of the occurrence of three cases of PML. Rituximab, an anti-CD20 mAb, is used in different neoplastic and autoimmune diseases and may soon enter the pharmacopeia of multiple sclerosis. It has been suggested that rituximab is a risk factor for PML; however, evidence of such a link is unclear. Antitumor necrosis factor-alpha agents are used in several autoimmune diseases. Several cases of demyelinating events of the nervous system have been reported, prompting a heightened surveillance of treated patients. Recent data are reassuring, suggesting that the incidence of such events is relatively low.
Summary: Neurologists must become familiar with neurological complications of new immunomodulatory treatments, a field situated at the interface of neurology, immunology and infection.
Mots-clé
Animals, Antibodies, Monoclonal/adverse effects, Antibodies, Monoclonal, Murine-Derived, Demyelinating Diseases/chemically induced, Demyelinating Diseases/drug therapy, Humans, Iatrogenic Disease/prevention & control, Immunologic Factors/adverse effects, Leukoencephalopathy, Progressive Multifocal/chemically induced, Leukoencephalopathy, Progressive Multifocal/immunology, Nervous System/drug effects, Nervous System/immunology, Risk Assessment/standards, Tumor Necrosis Factor-alpha/antagonists & inhibitors, Tumor Necrosis Factor-alpha/immunology
Pubmed
Web of science
Création de la notice
08/06/2010 16:22
Dernière modification de la notice
20/08/2019 13:35
Données d'usage